4514 Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices 

For Further Information Contact: 

Demetria Gardner, Immunization 

Services Division, National Center for 

Immunization and Respiratory Diseases, 

CDC, 1600 Clifton Road, NE., (E–05), 

Atlanta, Georgia 30333, telephone 404/ 

639–8836, fax 404/639–6258. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both the CDC 

and ATSDR. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–1490 Filed 1–30–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 71 FR 69211, dated 

November 30, 2006) is amended to 

reflect the establishment of the 

Extramural Research Program Office 

within the National Center for Injury 

Prevention and Control, coordinating 

Center for Environmental Health and 

Injury Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: After the functional statement 

for the Office of Communication 

Resources (CTC14), Office of the 

Director (CTC1), National Center for 

Injury Prevention and Control (CTC), 

insert the following: 

Extramural Research Program Office 

(CTC16). The Extramural Research 

Program Office (ERPO) plans, develops, 

coordinates, and evaluates extramural 

research activities in cooperation with 

centers, divisions, and offices within the 

Coordinating Center for Environmental 

Health and Injury Prevention. In 

carrying out its mission, the ERPO: (1) 

Directs the Extramural research program 

by planning, coordinating, developing, 

implementing, monitoring, and 

evaluating extramural research that is 

designed to address center priorities; (2) 

participates with divisions and offices 

within the center to establish research 

priorities for the center; (3) provides 

scientific leadership in the areas of 

extramural research supported by the 

center; (4) promotes and prepares 

initiatives to stimulate extramural 

research in relevant priority areas; (5) 

coordinates and conducts in-depth 

external peer review and secondary 

program relevance review of extramural 

research applications by use of 

consultant expert panels; (6) makes 

recommendations to the center director 

on award selections and staff members 

serve as the program officials in 

conjunction with CDC grants 

management and policy officials to 

implement and monitor the scientific, 

technical, and administrative aspects of 

awards; (7) facilitates scientific 

collaborations between external and 

internal investigators; (8) disseminates 

and evaluates extramural research 

progress, findings, and impact; and (9) 

assists the Office of Chief Science 

Officer, CDC, in developing extramural 

research policies and oversees the 

implementation of those policies within 

the center. 

Dated: January 9, 2007. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 07–417 Filed 1–30–07; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006N–0136] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

Interstate Shellfish Dealers Certificate 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled 

‘‘Interstate Shellfish Dealers Certificate’’

has been approved by the Office of 

Management and Budget (OMB) under 

the Paperwork Reduction Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of the Chief 

Information Officer (HFA–250), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301–827–

4659. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of October 13, 2006 (71 

FR 60545), the agency announced that 

the proposed information collection had 

been submitted to OMB for review and 

clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0021. The 

approval expires on January 31, 2010. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.fda.gov/ 

ohrms/dockets. 

Dated: January 25, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–1549 Filed 1–30–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[FDA 225–07–4300] 

Memorandum of Understanding 

Between the United States Food and 

Drug Administration and the Veterans 

Health Administration 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between FDA and 

the Veterans Health Administration. 

The purpose of this MOU is to enhance 

knowledge and efficiency by providing 

for the sharing of information and 

expertise related to the review and use 

of FDA-regulated drugs, biologics, and 

medical devices between the two 

agencies. The goals of the collaboration 

are to explore ways to: Further enhance 

information sharing efforts through 

more efficient and robust interagency 

activities; promote efficient utilization 

of tools and expertise for product risk 

identification, validation, and analysis; 

and build infrastructure and processes 

that meet the common needs for 

evaluating the safety, efficacy, and 

utilization of drugs, biologics, and 

medical devices. 

DATES: The agreement became effective 

January 23, 2007. 

FOR FURTHER INFORMATION CONTACT: 

Jeffrey Shuren, Office of Policy (HF–11), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–3360. 

mstockstill on PROD1PC62 with NOTICES